Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

Market Cap	40.52B +167.6%
Revenue (ttm)	4.20B +251.8%
Net Income	2.94B +317.1%
EPS	4.76 +317.5%
Shares Out	618.09M
PE Ratio	13.77
Forward PE	119.20
Dividend	0.12 (0.18%)
Ex-Dividend Date	Nov 7, 2025

Volume	9,912,541
Average Volume	5,983,780
Open	68.87
Previous Close	70.03
Day's Range	64.87 - 69.88
52-Week Range	23.46 - 83.00
Beta	0.89
RSI	58.82
Earnings Date	Mar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,023
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688336

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.94 billion, an increase of 317.09%.